V Fonseca

Summary

Affiliation: Tulane University
Country: USA

Publications

  1. ncbi Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial
    V Fonseca
    Department of Medicine, Tulane University, New Orleans, LA 70112, USA
    JAMA 283:1695-702. 2000
  2. ncbi Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients
    V Fonseca
    Department of Medicine, Tulane University Medical School, New Orleans, Louisiana 70112, USA
    Diabetes Care 23:354-9. 2000
  3. ncbi Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI
    V Fonseca
    Tulane University, New Orleans, LA 70112, USA
    Diabet Med 24:759-63. 2007
  4. ncbi Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus
    V Fonseca
    Endocrinology Department, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Horm Metab Res 40:427-30. 2008
  5. ncbi Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
    V Fonseca
    Endocrinology Department, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Diabetologia 50:1148-55. 2007
  6. ncbi An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia
    V Fonseca
    Department of Endocrinology, Tulane University Medical Center, New Orleans, LA 70112, USA
    Diabetes Obes Metab 13:814-22. 2011
  7. ncbi Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials
    L A Bazzano
    Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA 70112 2715, USA
    Diabet Med 25:924-32. 2008
  8. ncbi Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage
    V Fonseca
    Department of Medicine, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Diabetes Obes Metab 14:365-71. 2012
  9. ncbi Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes
    A Toprani
    Department of Family and Community Medicine Section of Preventive Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA
    Diabetes Obes Metab 13:276-80. 2011
  10. ncbi Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
    Faramarz Ismail-Beigi
    Department of Medicine, Division of Clinical and Molecular Endocrinology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106 4951, USA
    Lancet 376:419-30. 2010

Detail Information

Publications19

  1. ncbi Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial
    V Fonseca
    Department of Medicine, Tulane University, New Orleans, LA 70112, USA
    JAMA 283:1695-702. 2000
    ....
  2. ncbi Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients
    V Fonseca
    Department of Medicine, Tulane University Medical School, New Orleans, Louisiana 70112, USA
    Diabetes Care 23:354-9. 2000
    ..To determine the long-term effects of troglitazone as monotherapy or in combination with sulfonylureas or insulin regarding glycemic and lipid measures...
  3. ncbi Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI
    V Fonseca
    Tulane University, New Orleans, LA 70112, USA
    Diabet Med 24:759-63. 2007
    ..To determine whether the beneficial effects of carvedilol on insulin resistance (IR) are affected by the concomitant use of insulin sensitizers [thiazolidinediones (TZDs) and metformin]...
  4. ncbi Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus
    V Fonseca
    Endocrinology Department, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Horm Metab Res 40:427-30. 2008
  5. ncbi Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
    V Fonseca
    Endocrinology Department, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Diabetologia 50:1148-55. 2007
    ..This study assessed the efficacy and tolerability of vildagliptin added to insulin therapy in patients with type 2 diabetes...
  6. ncbi An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia
    V Fonseca
    Department of Endocrinology, Tulane University Medical Center, New Orleans, LA 70112, USA
    Diabetes Obes Metab 13:814-22. 2011
    ..To evaluate the benefits of initiating insulin at an earlier versus later treatment stage, and regimens with/without sulfonylurea (SU)...
  7. ncbi Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials
    L A Bazzano
    Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA 70112 2715, USA
    Diabet Med 25:924-32. 2008
    ..We systematically analysed evidence from randomized controlled trials (RCTs) examining the safety and efficacy of neutral protamine Hagedorn (NPH) insulin and glargine in the management of adults with Type 2 diabetes...
  8. ncbi Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage
    V Fonseca
    Department of Medicine, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Diabetes Obes Metab 14:365-71. 2012
    ..To investigate whether patients taking metformin for type 2 diabetes mellitus (T2DM) have improved glycaemic control without compromising tolerability by adding an agent with a complementary mechanism of action vs. uptitrating metformin...
  9. ncbi Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes
    A Toprani
    Department of Family and Community Medicine Section of Preventive Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA
    Diabetes Obes Metab 13:276-80. 2011
    ..The use of TZDs in clinical practice has the potential to increase morbidity and health care costs. The purpose of this study was to compare the incidence of CHF in TZD and non-TZD-treated patients in a clinical setting...
  10. ncbi Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
    Faramarz Ismail-Beigi
    Department of Medicine, Division of Clinical and Molecular Endocrinology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106 4951, USA
    Lancet 376:419-30. 2010
    ..We investigated whether reduction of blood glucose concentration decreases the rate of microvascular complications in people with type 2 diabetes...
  11. ncbi beta-blocker use and diabetes symptom score: results from the GEMINI study
    J B McGill
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Diabetes Obes Metab 9:408-17. 2007
    ..In this paper, we report the results of a prespecified secondary analysis of GEMINI that sought to determine the effect of these two beta-blockers on commonly reported symptoms...
  12. ncbi Management of the insulin resistance syndrome
    C Desouza
    Tulane University Health Sciences Center, Department of Medicine, Section of Endocrinology SL53, 1430 Tulane Avenue, New Orleans, LA 70112-2699, USA
    Curr Diab Rep 1:140-7. 2001
    ..Optimal treatment will not only improve glycemic control, but may also significantly lower cardiovascular disease...
  13. ncbi Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials
    V Fonseca
    Section of Endocrinology and Metabolism, Tulane University Health Sciences Centre, 1430 Tulane Avenue SL 53, New Orleans, LA 70112, USA
    Diabetologia 47:1914-23. 2004
    ....
  14. ncbi Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy
    A Jawa
    Department of Medicine, Section of Endocrinology, Tulane University Medical Center, New Orleans, Louisiana 70112-2699, USA
    J Clin Endocrinol Metab 91:31-5. 2006
    ..Alternative strategies for reducing microalbuminuria in high-risk patients who do not respond adequately to ACEI therapy such as African-Americans are needed...
  15. ncbi A comparison of long-term survivals of simultaneous pancreas-kidney transplant between African American and Caucasian recipients with basiliximab induction therapy
    R Zhang
    Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA
    Am J Transplant 7:1815-21. 2007
    ..AA may not have worse long-term outcomes than CA recipients of SPK with basiliximab induction and tacrolimus (TAC), mycophenolate acid (MFA) and steroid maintenance immunotherapy...
  16. ncbi Effects of intensive glucose lowering in type 2 diabetes
    Hertzel C Gerstein
    N Engl J Med 358:2545-59. 2008
    ..These findings identify a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00000620.)..
  17. ncbi Nontraditional risk factors for cardiovascular disease in diabetes
    V Fonseca
    Section of Endocrinology, Department of Medicine, Tulane University Medical Center, New Orleans, Louisiana 70112, USA
    Endocr Rev 25:153-75. 2004
    ..We will also discuss the impact of various therapies used in patients with diabetes on nontraditional risk factors...
  18. ncbi Increased serum homocysteine and sudden death resulting from coronary atherosclerosis with fibrous plaques
    Allen P Burke
    Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, Washington, DC, USA
    Arterioscler Thromb Vasc Biol 22:1936-41. 2002
    ..5 micromol/L). CONCLUSIONS: Increased serum homocysteine is associated with sudden death in the absence of acute coronary thrombosis, especially with concomitant diabetes, and with the presence of lipid-poor, fibrous plaques...
  19. ncbi Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
    Robert M Califf
    Duke Transitional Medicine Institute, Durham, NC 27715, USA
    Am Heart J 156:623-32. 2008
    ..The study was designed to evaluate whether reducing postprandial hyperglycemia, blockade of the renin-angiotensin-aldosterone system, or both interventions reduce the risk of T2DM or cardiovascular events in patients with IGT...